Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | DUT | P33316 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL594613 | 0.68 | LMNA (0.35) | LMNAMAPTALDH1A1 | |
| SCHEMBL19760167 | 0.67 | CRBN (0.44) | LMNACRBNDDB1ALDH1A1PKM | |
| SCHEMBL15412264 | 0.65 | MEN1 (0.32) | LMNAMAPT | |
| SCHEMBL9342861 | 0.64 | CRBN (0.55) | LMNACRBNDDB1 | |
| SCHEMBL8676867 | 0.64 | NPSR1 (0.49) | LMNAMAPTALDH1A1 | |
| SCHEMBL8564358 | 0.64 | LMNA (1.00) | LMNAMAPTALDH1A1 | |
| SCHEMBL4307805 | 0.63 | LMNA (0.49) | LMNAMAPTCCNE1CDK2 | |
| SCHEMBL1530734 | 0.63 | CRBN (1.00) | CRBNDDB1DUT | |
| SCHEMBL9563480 | 0.63 | CRBN (0.54) | LMNACRBNDDB1ALDH1A1PKM | |
| SCHEMBL21227587 | 0.61 | MAPT (0.37) | LMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280513-A1 | ENHANCING THE ANTIVIRAL EFFICACY OF RNA VIRUS INHIBITION BY COMBINATION WITH MODULATORS OF PYRIMIDINE METABOLISM | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-09-08 | — | — | US | claimed |
| WO-2021011572-A1 | ENHANCING THE ANTIVIRAL EFFICACY OF RNA VIRUS INHIBITION BY COMBINATION WITH MODULATORS OF PYRIMIDINE METABOLISM | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-01-21 | — | — | WO | claimed |
| WO-2025074343-A2 | PRODRUGS OF HUMAN DIHYDROOROTATE DEHYDROGENASE (hDHODH) INHIBITORS | DRUG DISCOVERY AND CLINIC S.R.L. (IT) | 2025-04-10 | — | — | WO | disclosed |
| US-20220280513-A1 | ENHANCING THE ANTIVIRAL EFFICACY OF RNA VIRUS INHIBITION BY COMBINATION WITH MODULATORS OF PYRIMIDINE METABOLISM | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-09-08 | — | — | US | disclosed |
| WO-2021011572-A1 | ENHANCING THE ANTIVIRAL EFFICACY OF RNA VIRUS INHIBITION BY COMBINATION WITH MODULATORS OF PYRIMIDINE METABOLISM | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-01-21 | — | — | WO | disclosed |
| US-20090270431-A1 | Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2007047793-A2 | CYCLOPENTENOL NUCLEOSIDE COMPOUNDS, INTERMEDIATES FOR THEIR SYNTHESIS AND METHODS OF TREATING VIRAL INFECTIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270431-A1 | Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections | REV1, NSUN2, ORC3 | LMNA 954/4885MAPT 4454/4885CRBN 1909/4885 |
| US-20220280513-A1 | ENHANCING THE ANTIVIRAL EFFICACY OF RNA VIRUS INHIBITION BY COMBINATION WITH MODULATORS OF PYRIMIDINE METABOLISM | EIF2AK2, RNGTT, RNMT | LMNA 4089/4885MAPT 2969/4885CRBN 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.